Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NDRA ENDRA Life Sciences	$3.58 +2.3%	$3.83	$2.90 ▼ $179.20	$2.64M	-0.21	141,932 shs	11,484 shs
NUWE Nuwellis	$0.24 -7.9%	$0.72	$0.21 ▼ $5.84	$1.04M	0.48	3.45 million shs	2.41 million shs
VRAY ViewRay		$0.34	$0.02 ▼ $4.96	$4.59M	0.81	7.51 million shs	108.50 million shs
VRAYQ ViewRay		$0.00	$0.00 ▼ $0.00	$18K	1.02	616 shs	103,897 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NDRA ENDRA Life Sciences	0.00%	+12.23%	+10.84%	-15.57%	-99.96%
NUWE Nuwellis	0.00%	-11.04%	-74.02%	-75.63%	-95.26%
VRAY ViewRay	0.00%	0.00%	0.00%	0.00%	0.00%
VRAYQ ViewRay	0.00%	0.00%	0.00%	+3.00%	+3.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NDRA ENDRA Life Sciences	3.1346 of 5 stars	3.5	5.0	0.0	0.0	2.2	0.0	1.3
NUWE Nuwellis	2.5524 of 5 stars	3.5	2.0	0.0	0.0	3.3	0.0	1.3
VRAY ViewRay	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRAYQ ViewRay	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NDRA ENDRA Life Sciences	3.00	Buy	$50.00	1,296.65% Upside
NUWE Nuwellis	3.00	Buy	$17.00	7,051.87% Upside
VRAY ViewRay	0.00	N/A	N/A	N/A
VRAYQ ViewRay	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NDRA, VRAYQ, NUWE, and VRAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	NUWE Nuwellis	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	NDRA ENDRA Life Sciences	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $50.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$4.77 per share	N/A
NUWE Nuwellis	$8.74M	0.12	N/A	N/A	$1.49 per share	0.16
VRAY ViewRay	$105.86M	0.00	N/A	N/A	$0.45 per share	0.00
VRAYQ ViewRay	$102.21M	0.00	N/A	N/A	N/A	NaN

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NDRA ENDRA Life Sciences	-$11.51M	-$172.04	N/A	N/A	N/A	N/A	-140.96%	-106.14%	8/13/2025 (Estimated)
NUWE Nuwellis	-$11.16M	-$18.24	N/A	N/A	N/A	-112.09%	-655.31%	-141.83%	8/12/2025 (Estimated)
VRAY ViewRay	-$107.33M	-$0.60	N/A	N/A	N/A	-104.30%	-120.48%	-42.39%	N/A
VRAYQ ViewRay	-$107.33M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest NDRA, VRAYQ, NUWE, and VRAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	NUWE Nuwellis	-$0.45	-$0.69	-$0.24	-$0.69	$2.50 million	$1.90 million
3/31/2025	Q4 2024	NDRA ENDRA Life Sciences	-$4.10	-$9.40	-$5.30	-$20.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
VRAY ViewRay	N/A	N/A	N/A	N/A	N/A
VRAYQ ViewRay	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NDRA ENDRA Life Sciences	N/A	3.85	3.85
NUWE Nuwellis	N/A	2.23	1.59
VRAY ViewRay	N/A	1.16	0.91
VRAYQ ViewRay	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NDRA ENDRA Life Sciences	1.19%
NUWE Nuwellis	3.13%
VRAY ViewRay	92.97%
VRAYQ ViewRay	15.47%

Insider Ownership

Company	Insider Ownership
NDRA ENDRA Life Sciences	0.04%
NUWE Nuwellis	1.60%
VRAY ViewRay	2.50%
VRAYQ ViewRay	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NDRA ENDRA Life Sciences	20	740,000	738,000	Not Optionable
NUWE Nuwellis	70	4.37 million	4.30 million	Not Optionable
VRAY ViewRay	295	183.40 million	178.82 million	Optionable
VRAYQ ViewRay	300	183.40 million	178.82 million	No Data

NDRA, VRAYQ, NUWE, and VRAY Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA, VRAYQ, NUWE, and VRAY Company Descriptions

ENDRA Life Sciences NASDAQ:NDRA

$3.58 +0.08 (+2.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.56 -0.02 (-0.56%)

As of 06/27/2025 07:04 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Nuwellis NASDAQ:NUWE

$0.24 -0.02 (-7.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.23 -0.01 (-4.50%)

As of 06/27/2025 07:58 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

ViewRay NASDAQ:VRAY

ViewRay NASDAQ:VRAYQ

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time